Herbal medicines in the treatment of psychiatric and neurological disorders

Low-Cost Approaches to Promote Physical and Mental Health: Theory, Research, and Practice

Volumn , Issue , 2007, Pages 119-138

  Akhondzadeh, Shahin ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 72049101248     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/0-387-36899-X_6     Document Type: Chapter

References (61)

1. Abdullaev, F. I. (2002). Cancer chemopreventive and tumoricidal properties of saffron (Crocus sativus L.). Experimental Biology and Medicine, 227, 20-25.
2. Abe, K., & Saito, H. (2000). Effects of saffron and its constituent crocin on learning behavior and long-term potentiation. Phytotherapy Research, 14, 149-152.
3. Akhondzadeh, S., Naghavi, H. R., Vazirian, M., Shayeganpour, A., Rashidi, H., & Khani, M. (2001a). Passionflower inthe treatment of generalized anxiety: A doubleblind and randomized trial with oxazepam. Journal of Clinical Pharmacy and Therapeutics, 26, 363-367.
4. Akhondzadeh, S., Kashani, L., Mobaseri, M., Hosseini, S. H., Nikzad, S., & Khani, M. (2001b). Passionflower inthe treatment of opiates withdrawal: a double-blind randomized controlled trial. Journal of Clinical Pharmacy and Therapeutics, 26, 369-373.
5. Akhondzadeh, S., & Noroozian, M. (2002). Alzheimer's disease: pathophysiology and Pharmacotherapy. Idrugs, 4, 1167-1172.
6. Akhondzadeh, S., Noroozian, M., Mohammadi, M., & Ohadinia, S. (2003a). Melissa officinalis extract inthe treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomised, placebo controlled trial. Journal of Neurology, Neurosurgery and Psychiatry, 74, 863-866.
7. Akhondzadeh, S., Noroozian, M., Mohammadi, M., & Ohadinia, S. (2003b). Salvia officinalis extract inthe treatment of patients with mild to moderate Alzheimer's disease: a double blind, randomized and placebo-controlled trial. Journal of Clinical Pharmacy and Therapeutics, 28, 53-59.
8. Akhondzadeh, S., Kashani, L., Fotouhi, A., & Jarvandi, S. (2003). Comparison of Lavandula angostofolia Mill. tincture and imipramine inthe treatment of mild to moderate depression: a double-blind, randomized pilot study. Progress in Neuropsychopharmacology and Biological Psychiatry, 27, 123-127.
9. Akhondzadeh, S., Fallah Pour, H., Afkham, K., Jamshidi, A. H., & Khalighi-Cigarodi, F. (2004). Comparison of Crocus sativus L. and imipramine inthe treatment of mild to moderate depression: a pilot double-blind randomized trial [ISRCTN45683816]. BMC Complementary and Alternative Medicine, 4, 12.
10. Akhondzadeh, S., Tamacebi-pour, N., Noorbala, A. A., Amini, H., Fallah Pour, H., Jamshidi, A. H., & Khani, M. (2005a). Crocus sativus L. Inthe treatment of mild to moderate depression: A double-blind, randomized and placebo controlled trial. Phytotherapy Research, 19, 25-29.
11. Akhondzadeh, S., Mohammadi, M. R., & Momeni F. (2005b). Passiflora incarnata intreatment of attention-deficit hyperactivity disorder inchildren and adolescents. Therapy, 2, 609-614.
12. Astin, J. A. (1998). Why patients use alternative medicine: results of a national study. Journal of the American Medical Association, 279, 1548-1553.
13. Balderer, G., & Borbely, A. A. (1985). Effect of valerian on human sleep. Psychopharmacology, 87, 406-409.
14. Becker, B., Bock, B., & Carmona-Barros, R. (2003). St John's Wort oral spray reduces withdrawal symptoms during quitting smoking. In: Society for Research on Nicotine and Tobacco 9th Annual Meeting, New Orleans, Louisiana.
15. Brue, A. W., & Oakland, T. D. (2002). Alternative treatments for attention deficit hyperactivity disorders: Does evidence support their use. Alternative Therapy Medicine, 8, 68-74.
16. Bullock, R. (2001). Drug treatment indementia. Current Opinion in Psychiatry, 14, 349-353.
17. Bullock, R. (2002). New drugs for Alzheimer's disease and other dementias. British Journal of Psychiatry, 180, 135-139.
18. Connor, K. M., & Davidson, J. R. (2002). A placebo-controlled study of Kava kava ingeneralized anxiety disorder. International Clinical Psychopharmacology, 17, 185-188.
19. Catania, M. A., Firenzuoli, F., & Crupi, A. (2003). Hypericum perforatum attenuates nicotine withdrawal signs inmice. Psychopharmacology, 169, 186-189.
20. Dean, A. J. (2005). Natural and complementary therapies for substance use disorders. Current Opinion in Psychiatry, 18, 271-276.
21. Delaveau, P., Guillemain, J., Narcisse, G., & Rousseau, A. (1989). Neurodepressive properties of essential oil of lavender. Comptes Rendus des Seances de la Societe de Biologie et de ses Filiales, 183, 342-348.
22. De Feudis, F. V. (1991). Gingko biloba extract (EGb761): pharmacological activities and clinical applications. Paris: Elsevier.
23. Donath, F., Quispe, S., & Diefenbach, K. (2000). Critical evaluation of the effect of valerian extract on sleep structure and sleep quality. Pharmacopsychiatry, 33, 47-53.
24. Evans, D. A., Funkenstein, H. H., & Albert, M. S. (1989). Prevalence of Alzheimer's disease ina community population of older persons: higher than previously reported. Journal of the American Medical Association, 262, 2551-2556.
25. Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999). The cholinergic hypothesis of Alzheimer's disease: a review of progress. Journal of Neurology, Neurosurgery and Psychiatry, 54, 137-147.
26. Gaster, B., & Holroyd, J. (2000). St. John's wort for depression: A systematic review. Archive of internal of Medicine, 160, 152-156.
27. Geldmacher, D. S., & Whitehouse, P. J. (1997). Differential diagnosis of Alzheimer's disease. Neurology, 48(Suppl. 6), S2-S9.
28. Gelenberg, A. J. (2000). St. John's Wort update. Biological Therapies in Psychiatry, 23, 22-24.
29. Hansgen, K. D., Vesper, J., & Ploch, M. (1994). Multicenter double-blind study examining the antidepressant effectiveness of the hypericum extract L160. Journal of Geriatric Psychiatry and Neurology, 7, S15-S18.
30. Hosseinzadeh, H., & Younesi, H. (2002). Petal and stigma extracts of Crocus sativus L. have antinociceptive and anti-inflammatory effects inmice. BMC Pharmacology, 2, 7.
31. Kanowski, S., & Hoerr, R. (1997). Proof of the efficacy of the gingko biloba special extract egb761 inoutpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer typeof multi-infarct dementia. Phytomedicine, 4, 215-222.
32. Kennedy, D. O., Scholey, A. B., Tildesley, N. T. J., Perry, E. K., & Wesnes, K. A. (2002). Modulation of mood and cognitive performance following acte adminstration of Melissa officinalis (lemon balm). Pharmacology and Biochemistry and Behavior, 72, 953-964.
33. Kim, H. L., Streltzer, J., & Goebert, D. (1999). St. John's wort for depression: A metaanalysis of well-defined clinical trials. Journal of Nervous and Mental Disease, 187, 532-539.
34. Kleijnen, J. (1992). Gingko biloba. Lancet, 340, 1136-1139
35. Le Bars, P. L., Katz, M. M., Berman, N., Itil, T. M., Freedman, A. M., & Schatzberg, A. F. (1997). A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. North American EGb Study Group. Journal of the American Medical Association, 278, 1327-1332.
36. Le Bars, P. L., Kieser, M., & Itil, K. Z. (2000). A 26-week analysis of a doubleblind, placebo-controlled trial of the ginkgo biloba extract EGb 761 indementia. Dementia, Geriatric and Cognition Disorder, 11, 230-237.
37. Lehmann, E., Kinzler, E., & Friedmann, J. (1996). Efficacy of a special Kava extract (Piper methysticum) Inpatients with states of anxiety, tension, excitedness of nonmental origin: A double-blind, placebo-controlled study of four weeks treatment. Phytomedicine, 3, 113-119.
38. Lieberman, S. (1998). Nutriceutical review of St. John's wort (hypericum perforatum) for the treatment of depression. Journal of Women's Health, 7, 177-182.
39. Linde, K., Ramirez, G., & Mulrow, C. D. (1996). St. John's wort for depression: An overview and meta-analysis of randomised clinical trials. BMJ, 313, 253-258.
40. Lindenberg, D., & Pitule-Schodel, H. (1990). Kava incomparison with oxazepam and anxiety disorders: A double-blind study of clinical effectiveness. Fortschr Medicine, 108, 49-54.
41. Livingston, G., & Katona, C. (2000). How useful are cholinesterase inhibitor inthe treatment of Alzheimer's disease? A number needed to treat analysis. International Journal of Geriatric Psychiatry, 15, 203-207.
42. Medical Economics. (2000). PDR (Physicians' Desk Reference) for Herbal Medicines (2nd edn). Montvale, NJ: Medical Economics Company.
43. McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984). Clinical diagnosis of AD: Report of NINCDS-ADRDA work group under the auspices of department of health and human services task force on AD. Neurology, 34, 939-944.
44. Noorbala, A. A., Akhondzadeh, S., Tamacebi-pour, N., & Jamshidi, A. H. (2005). Hydro-alcoholic extract of Crocus sativus L. versus fluoxetine inthe treatment of mild to moderate depression: A double-blind, randomized pilot trial. Ethnopharmacology, 97, 281-284.
45. Perry, E. K., Pikering, A. T., Wang, W. W., Houghton, P. J., & Perry, N. S. (1998). Medicinal plants and Alzheimer's disease: integrating ethnobotanical and contemporary scientific evidence. Journal of Alternative and Complementary Medicine, 4, 419-428.
46. Perry, E. K., Pikering, A. T., Wang, W. W., Houghton, P. J., & Perry, N. S. (1999). Medicinal plants and Alzheimer's disease: from etnobotany to phytotherapy. Journal of Pharmacology, 51, 527-534.
47. Pittler, M. H., & Ernst, E. (2000). Efficacy of kava extract for treating anxiety: Systematic review and meta-analysis. Journal of Clinical Psychopharmacology, 20, 84-89.
48. Richelson, E. (1994). Pharmacology of antidepressants-characteristic of the ideal drug. Mayo Clinic Proceeding, 69, 1069-1081.
49. Rios, J. L., Recio, M. C., Giner, R. M., & Manez, S. (1996). An update review of saffron and its active constituents. Phytotherapy Research, 10, 189-193.
50. Schelosky, L., Raffauf, C., & Jendroska, K. (1995). Kava and dopamine antagonism [letter]. Journal of Neurology, Neurosurgery and Psychiatry, 58, 639-640.
51. Schulz, V. (2003). Gingko extract or cholinesterase inhibitors inpatients with dementia: what clinical trials and guidelines fail to consider. Phytomedicine, 14(Suppl. 10), 74-79.
52. Schulz, V., Hansel R., & Tyler, V. E. (1998). Rational phytotherapy: a physicians' guide to herbal medicine (3rd ed.). Berlin, Germany: Springer-Verlag.
53. Sensenig, J., Marrongelle, J., Johnson, M., & Staverosky, T. (2001). Treatment of migraine with targated nutrition focused on improved assimilation and eliminiation. Alternative Medicine Review, 6, 488-494.
54. Sproule, B. A., Busto, U. E., & Buckle, C. (1999). The use of non-prescription sleep products inthe elderly. International Journal of Geriatric Psychiatry 14, 851-857.
55. Szatmari, S. Z., & Whitehouse, P. J. (2003). Vinpocetine for cognitive impairment and dementia (Cochrane Review). Cochrane Database Systematic Review CD003119.
56. Wake, G., Court, J., Pikering, A., Lewis, R., Wilkins, R., & Perry, E. (2000). CNS acetylcholine receptor activity in European medicinal plants traditionally used to improve failing memory. Journal of Ethnopharmacology, 69, 105-114.
57. Wheatley, D. (1999). Hypericum inseasonal affective disorder (SAD). Current Medical Research Opinion, 15, 33-7.
58. Xu, S. S., Gao, Z. X., & Weng, Z. (1995). Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer's disease. Zhongguo Yao Li Xue Bao, 16, 391-395.
59. Zhang, R. W., Tang, X. C., & Han, Y. Y. (1991). Drug evaluation of huperzine A in the treatment of senile memory disorders [in Chinese; English abstract]. Zhongguo Yao Li Xue Bao, 12, 250-252.
60. L'Abate, L., & Baggett, M. S. (1997). The self inthe family: A classification of personality, criminality, and psychopathology. New York: Wiley.
61. Rosenbaum, D. A. (2005). The Cinderella of psychology: The neglect of motor control inthe science of mental life and behavior. American Psychologist, 60, 308-317.